The company has not filed an annual or quarterly report since its FY2022 10-K, filed Mar 29, 2023. Its latest SEC filing is a 15-12G from May 9, 2023.
10-K for FY2022, filed Mar 29, 2023
The sections below describe the company as of the FY2022 annual report.
Develops and sells point-of-care tests for infectious diseases to medical laboratories and hospitals, government and public health organizations, and medical professionals and retailers.
10-K for FY2022, filed Mar 29, 2023
Customers buy diagnostic tests; product sales count when the goods are tendered, and payment is generally due 30 to 60 days after shipment. R&D study revenue is earned over the agreement, royalties are based on licensees’ product sales, and grants are invoiced as milestones are reached, conditions are met, and grantor approval is obtained.
10-K for FY2022, filed Mar 29, 2023Revenue from product sales are recognized and commissions are accrued when the customer obtains control of the Company’s product, which…View ↗
The Company’s payment terms vary by the type and location of the Company’s customer and products or services offered. Payment terms differ…View ↗
The Company’s contracts with customers often include promises to transfer products or services to a customer. Determining whether products…View ↗
The Company receives royalty revenue on sales by its licensee of products covered under patents that the Company owns. The Company does not…View ↗
Chembio receives government grants in support of R&D activities that are not associated with a customer-vendor relationship and therefore…View ↗
$49.5M
10-K for FY2022, filed Mar 29, 2023
$49.5M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product
Sold outright
10-K for FY2022, filed Mar 29, 2023 |
95%
FY2019: 84%
|
Product, FY2022
$47.1M Sources
|
Sold outright |
|
R&D Revenue
Recurring
|
0.2%
FY2019: 12%
|
R&D Revenue, FY2022
$113K Sources
|
Recurring |
|
Government Grant Income
|
2.4%
FY2019: 1.9%
|
Government Grant Income, FY2022
$1.2M Sources
|
|
|
License and Royalty Revenue
Licensed
|
2.3%
FY2019: 2.7%
|
License and Royalty Revenue, FY2022
$1.1M Sources
|
Licensed |
Hospitals, clinics, laboratories and medical professionals, government and public health organizations, and consumers buy globally, directly or through distributors.
10-K for FY2022, filed Mar 29, 2023Sales ChannelsView ↗
No. It lost $23.3M in FY2022.
10-K for FY2022, filed Mar 29, 2023
8-K, filed Apr 27, 2023
Biosynex Completes Acquisition of Chembio Diagnostics, Inc.View ↗
8-K, filed Apr 6, 2023
On April 6, 2023, Chembio Diagnostics, Inc. (the “Company”) received formal notice from the Listing Qualifications Staff (the “Staff”) of…View ↗
Grew. Revenue grew 43% in 4 years, from $34.6M in FY2018 to $49.5M in FY2022, about 9% a year.
Loading...
